With biopharma pouring more money than ever into weight loss medicines, physicians would like to see improved GLP-1 drugs. But the goals of the two parties are not in full alignment, according to a new study from financing partner DNB Markets and strategic advisory firm Back Bay Life Science Advisors.
Read MoreRobotic surgery is primed for an acceleration in activity – both in its clinical utilization as well as its strategic importance to the venture community and consolidators alike.
Given the significant opportunity to grow the overall market, the next wave of exciting robotic surgery innovations has caught the eye of medtech investors.
Read More